The Brown Laboratory pursues cutting-edge research focused on the treatment and prevention of breast cancer. This research is divided into three major areas:
Novel Targets for the Treatment of Triple-negative Breast Cancer
Using genomic, proteomic and metabolomic approaches, these projects focus on the identification of therapeutic compounds that are both more effective and less toxic for the treatment of ER-negative, PR-negative, HER2-negative, or “triple-negative”, breast cancers.
- Discovery of Phosphatases Critical for the Growth and Tumorigenicity of ER-negative Breast Cancers
- Inflammatory Genes Differentially Regulated in ER-negative Breast Cancer
- Targeting Death Pathways for the Prevention of ER-negative Breast Tumors
- Identification of Transcription Factors Critical for the Growth and Treatment of Breast Cancer
Identification and Targeting of Signaling Pathways Critical for the Prevention of ER-negative Breast Cancer
The prevention of breast cancer is a primary focus of research within the Brown Laboratory. The following projects utilize a broad range of techniques aimed at identifying novel chemopreventive agents for breast cancer.
- Targeting Breast Cancer Using RXR-Specific Retinoids
- Targeting Signaling Pathways for the Treatment and Prevention of Breast Cancer
- Suppression of Growth and Transformation of Breast Cancer Stem Cells by Rexinoids
- Defining Novel Targets for the Treatment of ER-negative Breast Cancers
Targeting Transcription Factors for the Prevention and Treatment of Breast Cancer
The identification of potential transcription factors critical for breast cancer development and growth is the focus of the third area of research within the Brown Laboratory. These projects center on determining the transcription factors that play key roles in the development of ER-negative and/or ER-positive breast cancers.